Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug a♣pproved by FDA for Alzheimer's disease in the Uni≈ted States. Its treatment reaches the target dose and has low toxic andΩ side effects. It has been widely recognized by our medical community, and good toleran¶ce is its biggest advantage. In October 1999, Donepezil was l≈aunched in China under the trade name "Aricept", which is the main chemical drug a÷gainst Alzheimer's disease. At present, CFDA has approved a number of dom₽estic enterprises to produce donepezil preparations, the main dosage forms are tablets, ±capsules, dispersive tablets, oral disintegrating table±ts.

key word:

domestic preparations

Category:

API

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry± finance platform company integrating pharmaceutical, intelligent medical, bio pharmaceutical R&aβmp;D, industrial production and sales.

The chemical reactions involved in the existing products include Foucault reaction, nitratio↑n reaction, sulfonation reaction, hydrogenation reaction, fluorination reaction, chlorina₽tion reaction, bromination reaction, diazotization reaction, format reaction, etc.

Treatment of mild to moderate Alzheimer's syndroπme. It is the second drug approved by FDA for Alzheimer's disease →in the United States. Its treatment reaches the target dose and has lo<w toxic and side effects. It has been widely recognized by ou>r medical community, and good tolerance is its biggest advantage. In ↔October 1999, Donepezil was launched in China under the trade name "Aricept",ε which is the main chemical drug against Alzheimer's disease. At present, CF↕DA has approved a number of domestic enterprises to produce donepezil preparations≈, the main dosage forms are tablets, capsules, dispersive tablets, oral disintegrating table ts.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4)  inhibitor developed by Merck. In October 2006, Sitagliptin phosphate Januvia was approved± by FDA as the first DPP4 inhibitor for the treatment of type ⅱ diabetes mellitus. The cha∞racteristics of this drug are that it can stimulate insul₩in secretion while reducing hunger without causing weight gain. Hypoglycemia and edemaλ will not occur, and it is suitable for diabetic patients with poor blood glucose control and frequ<ent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutic♥al enterprise that is market-oriented and realizes industrial development throug→h R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important products for the •treatment of arthritis. It is well tolerated and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotr"iene receptor antagonists. In clinical application, it has good therapeutic ef♦fect on atopic asthma and other types of bronchial asthma, and the mar÷ket prospect is huge. In the major category of asthma drugs★, leukotriene receptor antagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise t•hat is market-oriented and realizes industrial development through R&D innovatio≠n and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved ✔by FDA for Alzheimer's disease in the United States. Its treatment reaches the target doδse and has low toxic and side effects. It has been widely recogni‌zed by our medical community, and good tolerance is its b∏iggest advantage. In October 1999, Donepezil was launched in China under the  trade name "Aricept", which is the main chemical drug against Alzheimer's disease. A←t present, CFDA has approved a number of domestic enterprises to pr oduce donepezil preparations, the main dosage forms are tablet↑s, capsules, dispersive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/γPfizer), a direct oral factor Xa inhibitor, was approved for use in t≤he 27 EU member states. The world's first drug approved to prevent venous thromboembolism (₽VTE) in adult patients undergoing elective hip or knee replacement. From★ June 2019 to June 2020, the annual sales of apixaban products ove®rseas reached about $15.4 billion, with a year-on-year growth of nea§rly 32%, and the API consumption reached about 23,960 kg, with a year-on-yea✘r growth of about 28%. Compared with its main competitor, Riva®roxaban, the drug's annual overseas sales are about $4.5 billion highe r.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-or♦iented and realizes industrial development through R&D innovation and t§echnology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzβyme. On December 29, 2004, it was approved by FDA for the treatmen♣t of refractory or relapsed acute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmac&eutical enterprise that is market-oriented and realizes industrial development through R&D i☆nnovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other services, E-mail: 2880705932@qq.com

Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Ltd.